title: The hypnotic zolpidem increases the synchrony of BOLD signal fluctuations in widespread brain networks during a resting paradigm.
abstract: Networks of brain regions having synchronized fluctuations of the blood oxygen level-dependent functional magnetic resonance imaging (BOLD fMRI) time-series at rest, or "resting state networks" (RSNs), are emerging as a basis for understanding intrinsic brain activity. RSNs are topographically consistent with activity-related networks subserving sensory, motor, and cognitive processes, and studying their spontaneous fluctuations following acute drug challenge may provide a way to understand better the neuroanatomical substrates of drug action. The present within-subject double-blind study used BOLD fMRI at 3T to investigate the functional networks influenced by the non-benzodiazepine hypnotic zolpidem (Ambien). Zolpidem is a positive modulator of γ-aminobutyric acid(A) (GABA(A)) receptors, and engenders sedative effects that may be explained in part by how it modulates intrinsic brain activity. Healthy participants (n=12) underwent fMRI scanning 45 min after acute oral administration of zolpidem (0, 5, 10, or 20mg), and changes in BOLD signal were measured while participants gazed at a static fixation point (i.e., at rest). Data were analyzed using group independent component analysis (ICA) with dual regression and results indicated that compared to placebo, the highest dose of zolpidem increased functional connectivity within a number of sensory, motor, and limbic networks. These results are consistent with previous studies showing an increase in functional connectivity at rest following administration of the positive GABA(A) receptor modulators midazolam and alcohol, and suggest that investigating how zolpidem modulates intrinsic brain activity may have implications for understanding the etiology of its powerful sedative effects.
authors.affiliation: Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA. slicata@mclean.harvard.edu
authors.forename: Stephanie C
authors.initials: SC
authors.lastname: Licata
authors.forename: Lisa D
authors.initials: LD
authors.lastname: Nickerson
authors.forename: Steven B
authors.initials: SB
authors.lastname: Lowen
authors.forename: George H
authors.initials: GH
authors.lastname: Trksak
authors.forename: Robert R
authors.initials: RR
authors.lastname: Maclean
authors.forename: Scott E
authors.initials: SE
authors.lastname: Lukas
mesh_terms: D000328:Adult; D005260:Female; D058785:GABA-A Receptor Agonists / Q000494:pharmacology*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008297:Male; D009415:Nerve Net / Q000187:drug effects* / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology*; D012146:Rest / Q000502:physiology*; D055815:Young Adult; D000077334:Zolpidem
chemical_list: D058785:GABA-A Receptor Agonists; D006993:Hypnotics and Sedatives; D011725:Pyridines; D000077334:Zolpidem